Polosa R, Holgate S T
Medicina (Firenze). 1989 Oct-Dec;9(4):422-4.
Bradykinin (Bk) is a potent bronchoconstrictor agent which may contribute to the pathogenesis of bronchial asthma. Recently we have shown that repeated bronchial challenge with this agonist in asthmatics produced a specific loss of responsiveness. In vitro studies suggest that this phenomenon may be due to generation of protective prostaglandins. In this study we investigated whether flurbiprofen (F) pretreatment inhibited Bk tachyphylaxis. The efficacy of F was demonstrated by the total suppression of whole blood TxB2 formation. In addition, a time-course study of the tachyphylactic response was carried out. Refractoriness in response to inhaled Bk occurred in all subjects. The mean PC20 Bk increased from 0.07 to 0.41 mg/ml with consecutive inhalation tests after placebo. Even in the presence of demonstrable cyclooxygenase inhibition, no effect of F was observed in inhibiting Bk tachyphylaxis the mean PC20 Bk still increasing from 0.10 to 0.47 mg/ml. Tachyphylaxis was still present at 6 h, but not in all subjects at 24 h. This study demonstrated that release of protective prostaglandins in the airway after Bk stimulation does not account for the loss of responsiveness following repeated exposure to Bk. At least 24 h should separate Bk inhalations to avoid tachyphylaxis. A possible mechanism of this phenomenon is discussed.
缓激肽(Bk)是一种强效支气管收缩剂,可能参与支气管哮喘的发病机制。最近我们发现,哮喘患者反复用这种激动剂进行支气管激发试验会导致特异性反应性丧失。体外研究表明,这种现象可能是由于保护性前列腺素的产生。在本研究中,我们调查了氟比洛芬(F)预处理是否能抑制Bk快速减敏。F的有效性通过全血TXB2生成的完全抑制得以证明。此外,还进行了快速减敏反应的时间进程研究。所有受试者对吸入Bk均出现反应性下降。安慰剂后连续吸入试验中,平均PC20 Bk从0.07增加到0.41 mg/ml。即使存在可证实的环氧化酶抑制作用,也未观察到F对抑制Bk快速减敏有作用,平均PC20 Bk仍从0.10增加到0.47 mg/ml。快速减敏在6小时时仍然存在,但在24小时时并非所有受试者都存在。本研究表明,Bk刺激后气道中保护性前列腺素的释放并不能解释反复接触Bk后反应性的丧失。Bk吸入之间至少应间隔24小时以避免快速减敏。本文讨论了这一现象的可能机制。